Physician PracticeResearch Use Only

SS-31

Elamipretide — a mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane and binds cardiolipin. In clinical trials for heart failure and mitochondrial disease.

LongevityMitochondrialCardiolipinInjectableClinical Trials
QUICK FACTS
GENERIC NAMEElamipretide (SS-31 / MTP-131)
CLASSMitochondria-targeted tetrapeptide
MECHANISMCardiolipin binding — inner mitochondrial membrane stabilization
EVIDENCE STATUSInvestigational/clinical-trial compound
WADA STATUSNot prohibited (verify current list)
Overview

SS-31 (Elamipretide, MTP-131) is a synthetic tetrapeptide that selectively concentrates in the inner mitochondrial membrane (IMM) at a ratio approximately 5,000-fold over cytosol. Its primary mechanism involves high-affinity binding to cardiolipin — the signature phospholipid of the inner mitochondrial membrane critical for electron transport chain function.

Cardiolipin plays a structural and functional role in organizing electron transport chain complexes into supercomplexes that optimize ATP production efficiency. Age, disease, and metabolic stress are associated with cardiolipin oxidation and redistribution, disrupting ETC function. SS-31 is proposed to stabilize cardiolipin and restore ETC efficiency.

Clinical trials have investigated SS-31/elamipretide in heart failure (STARGLO and LEAF trials) and rare mitochondrial diseases. These provide human safety data but efficacy results have been mixed. Physician practice use for longevity extrapolates from the disease-context data.

Research Areas
Mitochondrial inner membrane researchCardiolipin biologyHeart failure researchMitochondrial disease researchEnergy production pathwayLongevity/aging research
Available Evidence3 categories
Human (clinical trials)Multiple Phase I/II trials in heart failure (STARGLO, LEAF) and mitochondrial disease. Human safety profile established in trial populations. Efficacy endpoints have been mixed.
In VitroExtensive cellular evidence for cardiolipin binding, inner membrane stabilization, and restoration of electron transport chain efficiency. Well-characterized mechanism.
UncertainLongevity applications in healthy adults are physician practice extrapolation from disease-context trial data. Optimal dosing not established.
Documented Research Benefits6 documented
Cardiolipin binding
in vitro / preclinical
Inner mitochondrial membrane support
in vitro
ETC efficiency restoration
preclinical / limited human
Heart failure research
human trials
Energy production support
preclinical
Longevity research
physician practice
Research Pairings3 common
MOTS-c
Primary longevity pairing. SS-31 as mitochondrial foundation → MOTS-c for AMPK signaling. Sequential or concurrent physician practice approach.
View MOTS-c →
NAD+
Concurrent energy support — different mitochondrial mechanism. Three-compound longevity stack.
View NAD+ →
BPC-157 / TB-500
Added in some recovery-combined longevity protocols.
View BPC-157 →

What are you researching?

Tell us your focus area and we’ll send a personalized research guide.

Safety & Regulatory Status

SS-31/Elamipretide is not FDA-approved for any indication. Research use only. Injection site reactions are the primary adverse effect reported in clinical trials. Not currently WADA-prohibited (verify current list). All information for educational reference only.

Get the Research Guide

Research summaries, evidence tiers, and COA-verified sourcing. Published by Forge Scientific. No spam.